Vericel Corporation (VCEL)
| Market Cap | 1.77B |
| Revenue (ttm) | 118.34M |
| Net Income (ttm) | 145,000 |
| Shares Out | 45.27M |
| EPS (ttm) | 0.00 |
| PE Ratio | 13,003.33 |
| Forward PE | 76.34 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $39.01 |
| Previous Close | $38.52 |
| Change ($) | 0.49 |
| Change (%) | 1.27% |
| Day's Open | 38.39 |
| Day's Range | 37.93 - 39.60 |
| Day's Volume | 574,564 |
| 52-Week Range | 7.25 - 39.60 |
Record Quarterly and Full-Year Total Revenues
CAMBRIDGE, Mass., Jan. 08, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that...
CAMBRIDGE, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that...
Vericel is a high growth, disruptive biotechnology company with annual sales increasing at a 30% rate prior to the COVID-19 pandemic. The Company's tissue repair and restoration products are p...
The company's earnings are expected to increase exponentially in 2021
CAMBRIDGE, Mass., Dec. 18, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that...
Vericel is a low-risk, high-quality small biotech with high growth potential. The business is already profitable with 70% gross profit margin and no debt on the balance sheet.
Vericel Corporation (VCEL) CEO Nick Colangelo on Q3 2020 Results - Earnings Call Transcript
Total Net Revenues of $32.3 Million and Net Income of $3.6 Million
Technology won't always be on top. There's a bunch of budding industries that could prove to be winners over the next 5 years.
CAMBRIDGE, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced pres...
Vericel Corp (VCEL) has been struggling lately, but the selling pressure may be coming to an end soon.
CAMBRIDGE, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the ...
Double-Digit Revenue, Implant and Biopsy Growth for MACI in the Quarter and Record Monthly Biopsies in September
CAMBRIDGE, Mass., Oct. 09, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, will host a virtual ...
CAMBRIDGE, Mass., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ: VCEL) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the recently ...
CAMBRIDGE, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced p...
CAMBRIDGE, Mass., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced t...
YAVNE, Israel and CAMBRIDGE, Mass., Aug. 25, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD) and its U.S. commercial partner Vericel Corporation (NASDAQ: VCEL) today announced that th...
Vericel Corporation (VCEL) CEO Nick Colangelo on Q2 2020 Results - Earnings Call Transcript
Product Revenues of $20.0 Million Reported for the Second Quarter
CAMBRIDGE, Mass., July 22, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced th...
Investors need to pay close attention to Vericel (VCEL) stock based on the movements in the options market lately.
Second Quarter Net Product Revenues Expected to be Approximately $20 Million Second Quarter Net Product Revenues Expected to be Approximately $20 Million
CAMBRIDGE, Mass., June 30, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ: VCEL) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Admin...
Identifying toxic stocks and discarding them at the right time is the key to guard your portfolio from big losses.
Vericel's (VCEL) CEO Nick Colangelo on Q1 2020 Results - Earnings Call Transcript
Shares of Vericel (NASDAQ:VCEL) rose 2.2% after the company reported Q1 results. Quarterly Results Earnings per share fell 42.86% year over year to ($0.10), which missed the estimate of ($0.08).
Vericel Corporation: A Must-Have Biotech Post-COVID-19 Sell-Off - Behind The Idea
Vericel Is Substantially Undervalued Given Strong Balance Sheet, Profitability And Competitive Advantages
Accurately identifying toxic stocks and abandoning or short selling those at the right time is the key to safeguard your portfolio from big losses.
Vericel Corp (VCEL) CEO Dominick Colangelo on Q4 2019 Results - Earnings Call Transcript
Vericel (VCEL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
As of late, it has definitely been a great time to be an investor in Vericel.
The optimism regarding small businesses remains near an all-time high albeit a slowing U.S. economy.
U.S. stocks are heavily exposed to the domestic economy where data continues to improve. And even if skeptics worry about the virus outbreak, developed markets are more stable than emerging ma...
YAVNE, Israel and CAMBRIDGE, Mass., Jan. 06, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD) and its U.S. commercial partner Vericel Corporation (NASDAQ: VCEL) today announced that th...
Vericel has been struggling lately, but the selling pressure may be coming to an end soon.
Surprise Jump In Epicel Sales Highlights 'Outstanding' 3Q For Vericel
CAMBRIDGE, Mass., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced th...
Shares jumped following upbeat third-quarter results and a guidance boost.
Vericel Corporation (VCEL) CEO Nick Colangelo on Q3 2019 Results - Earnings Call Transcript
Vericel Corp (NASDAQ: VCEL), a commercial-stage company that specializes in advanced cell therapies for treating patients with knee cartilage defects and severe burn wounds, is investment-wort...
CAMBRIDGE, Mass. and YAVNE, Israel, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ: VCEL) and MediWound Ltd. (NASDAQ: MDWD) today announced initiation of the NexoBrid® expande...
CAMBRIDGE, Mass., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced t...
CAMBRIDGE, Mass., Sept. 18, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced t...
Vericel Corporation's (VCEL) CEO Nick Colangelo on Q2 2019 Results - Earnings Call Transcript
Vericel's newly acquired burn care product, NexoBrid, is revolutionary, creating a "new paradigm" in burn care.
Vericel Corporation (VCEL) CEO Nick Colangelo on Q1 2019 Results - Earnings Call Transcript
About VCEL
Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets in the United States. It markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of patients with deep-dermal or full-thickness burns.... [Read more...]
| Industry Biotechnology | IPO Date Feb 4, 1997 |
| CEO Dominick Colangelo | Employees 241 |
| Stock Exchange NASDAQ | Ticker Symbol VCEL |
Financial Performance
In 2019, Vericel's revenue was $117.85 million, an increase of 29.71% compared to the previous year's $90.86 million. Losses were -$9.67 million, 18.8% more than in 2018.
Analyst Forecasts
According to 8 analysts, the average rating for Vericel stock is "Strong Buy." The 12-month stock price forecast is 36.21, which is a decrease of -7.18% from the latest price.